ArticleFrontiers in endocrinology2026
Investigating the association between low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and the risk of carotid artery plaque in patients with first-ever ischemic stroke based on different glucose metabolic conditions.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated the association between the low-density lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio and carotid plaque risk in patients with first-ever ischemic stroke (IS). We focused on analyzing the differences in this association across different Glucose Metabolic Conditions, preliminarily explored the roles of glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) in this association, and thereby provided a basis for future prospective studies and risk assessment of IS events. Methods: This retrospective study included 12,166 patients hospitalized for first-time IS at the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from January 1, 2013, to May 1, 2023. The LDL-C/HDL-C-carotid plaque risk association across glucose metabolism statuses was assessed employing logistic regression, stratified analysis, and exploratory mediation analyses. Results: Of 12,166 participants, 9,469 (77.8%) had carotid plaque. Univariate logistic regression showed that LDL-C/HDL-C had a stronger association with the risk of carotid plaque formation than other lipid parameters (LDL-C, total cholesterol, and triglycerides). Multivariate analysis confirmed a significant positive association. Stratified analyses revealed that the association between LDL-C/HDL-C and plaque risk was relatively stronger in the Pre-DM cohort (odds ratio [OR]: 1.233, 95% confidence interval [CI]: 1.093-1.391), followed by patients with diabetes mellitus (OR: 1.178, 95% CI: 1.074-1.293); no significant association appeared in individuals with normal glucose regulation. Exploratory mediation analysis showed HbA1c and FPG accounted for 11.5% and 10.5% of the LDL-C/HDL-C-carotid plaque risk association, respectively. Conclusion: The findings of this study present that elevated LDL-C/HDL-C was significantly associated with carotid atherosclerosis in patients with IS, and this association was particularly stronger in the Pre-DM cohort. HbA1c and FPG had a certain moderating effect on this association, suggesting that the Pre-DM stage is a potential intervention window for focusing on LDL-C/HDL-C. LDL-C/HDL-C may serve as a reference indicator for clinically assessing the synergistic risk of "lipid-glucose co-morbidity," which holds significant value for the secondary prevention of IS events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.